Drugs@FDA: FDA-Approved Drugs
Biologic License Application (BLA): 761215
Company: ELI LILLY CO
Company: ELI LILLY CO
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
REZVOGLAR | INSULIN GLARGINE-AGLR | 3ML(100UNITS/ML) | INJECTABLE;INJECTION | Prescription | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
11/16/2022 | ORIG-2 | Approval | N/A |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761215s000Orig2s000.lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761215Orig2s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761215Orig2s000TOC.cfm | ||
12/17/2021 | ORIG-1 | Approval | N/A |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761215s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761215Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761215Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
08/09/2024 | SUPPL-5 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761215s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761215Orig1s005ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
08/09/2024 | SUPPL-5 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761215s005lbl.pdf | |
11/16/2022 | ORIG-2 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761215s000Orig2s000.lbl.pdf | |
12/17/2021 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761215s000lbl.pdf |